Is Kintara Therapeutics, Inc. (KTRA) a Buy, Sell, or Hold?
Kintara Therapeutics, Inc.
NASDAQ:KTRA
$0.2154 USD
-$0.01 (-6.31%)
- Volume
- 3.55M
- Average Volume
- 82.94K
- Market Capitalization
- $11.99M
- P/E Ratio
- -0.34
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $26.21
- Year Low
- $0.20
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.15
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jeffrey A. Bacha |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | KTRA |
| CUSIP | 49720K200 |
| CIK | 0001498382 |
| Web | https://www.kintara.com |
| Phone | 858 350 4364 |
| Currency | USD |
| Employees | 1 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.15 |
| Quick Ratio | 1.15 |
| Cash Ratio | 1.04 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.44 |
| Price / Cash Flow | -0.45 |
| Price / Book | 0.56 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 4 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.63 |
| Trailing P/E Ratio | -0.34 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-30.06M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -153.51% |
| Return on Assets | -103.81% |
Financials Score
| AltmanZ Score | -6.66 |
| Piotroski Score | 1.00 |
| Working Capital | 915.38K |
| Total Assets | 29.7M |
| Ebit | -7.09M |
| Market Cap | 11.99M |
| Total Liabilities | 6.51M |
Poll Results
About Kintara Therapeutics, Inc. (NASDAQ:KTRA) Stock
Kintara Therapeutics, Inc. operates as a clinical-stage biotechnology firm, dedicated to pioneering and commercializing anti-cancer treatments for patients. Central to its pipeline are two compounds nearing Phase III trials. One, VAL-083, is a DNA-targeting agent developed to combat drug-resistant solid tumors, including challenging conditions like glioblastoma multiforme, alongside other solid tumor types such as ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The other, REM-001, is a photodynamic therapy specifically targeting cutaneous metastatic breast cancer. The company has forged a strategic alliance with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to facilitate the production and sale of VAL-083 within the Chinese market. Incorporated in 2009, K ... intara maintains its headquarters in San Diego, California. Its current identity as Kintara Therapeutics, Inc. was adopted in August 2020, succeeding its former name, DelMar Pharmaceuticals, Inc.
Frequently Asked Questions
-
What is the current Kintara Therapeutics, Inc. (KTRA) stock price?
-
Kintara Therapeutics, Inc.(NASDAQ:KTRA) stock price is $0.2154 in the last trading session. During the trading session, KTRA stock reached the peak price of $26.214998 while $0.2049 was the lowest point it dropped to. The percentage change in KTRA stock occurred in the recent session was --6.31% while the dollar amount for the price change in KTRA stock was -$-0.01.
-
KTRA's industry and sector of operation?
-
The NASDAQ listed KTRA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of KTRA?
-
Jeffrey A. Bacha | Founder
Robert E. Hoffman | President, Chief Executive Officer, Chief Financial Officer & Chairman of the Board
Greg A. Johnson | Acting Head of Operations
|
| -
How many employees does KTRA have?
-
Number of KTRA employees currently stands at 1. KTRA operates from 12707 High Bluff Drive, San Diego, CA 92130, US.
-
Link for KTRA official website?
-
Official Website of KTRA is: https://www.kintara.com
-
How do I contact KTRA?
-
KTRA could be contacted at phone #858 350 4364 and can also be accessed through its website. KTRA operates from 12707 High Bluff Drive, San Diego, CA 92130, US.
-
How many shares of KTRA are traded daily?
-
The average number of KTRA shares traded daily for last 3 months was 82.94K.
-
What is the market cap of KTRA currently?
-
The market value of KTRA currently stands at $11.99M with its latest stock price at $0.2154